Clinical trial
Quetiapine Fumarate Bipolar Maintenance Monotherapy
NCT00314184 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00314184 |
|---|---|
| Title | Quetiapine Fumarate Bipolar Maintenance Monotherapy |
| Official title | Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients |
| Acronym | SPaRCLe |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | quetiapine fumarate |
| Enrollment | 1,255 |
| Start date | Mar 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Apr 13, 2006 |
| Last update posted | Dec 22, 2008 |
| Countries | Argentina, Bulgaria, Colombia, India, Lithuania, Malaysia, Mexico, Peru, Philippines, Romania, Russia, Taiwan and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: